MONTPELLIER, France--(BUSINESS WIRE)--Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN), a biotech company specializing in the treatment of inner ear diseases, today announces that it has obtained Investigational New Drug (IND) status from the FDA for SENS-111, enabling the Company to initiate a clinical study in acute severe vertigo.
The FDA’s approval validates the preclinical and clinical trials led by Sensorion within the framework of its SENS-111 program, and notably the results obtained from 100 healthy volunteers in a phase 1b clinical trial. The latter helped confirm the compound’s safety and pharmacokinetic profile and provided guidance regarding the caloric test’s use within this population.
All the results of the phase 1b trial will be presented at two upcoming annual scientific conferences:
The American Academy of Otolaryngology-Head and Neck Surgery
Foundation (AAO-HNSF), September 18-21, 2016, in San Diego, California
Poster: SENS-111, H4 Antagonist for Treatment of Peripheral Vertigo, Is Safe
The European Association for Clinical Pharmacology and Therapeutics
(EACPT), October 6-9, 2016, in Opatija, Croatia
Oral presentation: The effect of SENS-111, a new H4R antagonist, on vertigo induced by caloric test in healthy volunteers is related to plasma concentrations
The aim of the phase 2 study, which is expected to begin during the second half of 2016, will be to prove SENS-111’s efficacy in treating the symptoms in patients with acute severe vertigo. The international study will notably be undertaken in the United States and Europe.
Pierre Attali, Sensorion’s Chief Medical Officer, comments: “The FDA’s approval to begin our first phase 2 clinical trial of SENS-111 is a major strategic milestone for Sensorion. It reflects a real need for easy-to-administer drugs to treat vertigo crisis and confirms Sensorion’s ability to rapidly take its R&D programs to the clinical stage. Our technological platform, which is capable of identifying molecules of therapeutic interest for inner ear disorders, active through systemic administration, plays a pivotal role in this process. Given the results demonstrated by SENS-111 in preclinical trials and the phase 1b study, we are confident in the success of this new study, which we expect to initiate during the second half of this year.”
There is currently a clear unmet medical need for new effective and well-tolerated treatments to alleviate the symptoms of vertigo crises that effect some 82 million patients worldwide1.
1 Source: Alcimed, Sensorion
ISIN code: FR0012596468